Global Prostate Cancer Diagnostics Solution 麻豆原创 Research Report 2025

Publication ID:

PB502253853

Publication Date:

February 13, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

The global market for Prostate Cancer Diagnostics Solution was valued at US$ 15590 million in the year 2024 and is projected to reach a revised size of US$ 26180 million by 2031, growing at a CAGR of 7.8% during the forecast period.
The prostate is a walnut-sized gland located behind the base of a man鈥檚 penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.Prostate cancer diagnostics solution refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.

North American market for Prostate Cancer Diagnostics Solution is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Prostate Cancer Diagnostics Solution is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Prostate Cancer Diagnostics Solution in Age Below 55 is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Prostate Cancer Diagnostics Solution include OPKO, Genomic Health, Abbott, Beckman Coulter, Siemens Healthcare, bioMeriux, Roche, MDx Health, DiaSorin, Myriad Genetics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Prostate Cancer Diagnostics Solution, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Prostate Cancer Diagnostics Solution.
The Prostate Cancer Diagnostics Solution market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Prostate Cancer Diagnostics Solution market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Prostate Cancer Diagnostics Solution companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
OPKO
Genomic Health
Abbott
Beckman Coulter
Siemens Healthcare
bioMeriux
Roche
MDx Health
DiaSorin
Myriad Genetics
Ambry Genetics
Segment by Type
Tumor Biomarker Tests
Imaging
Biopsy
Other
Segment by Application
Age Below 55
Age 55-75
Age Above 75
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Prostate Cancer Diagnostics Solution company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Prostate Cancer Diagnostics Solution 麻豆原创 Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Tumor Biomarker Tests
1.2.3 Imaging
1.2.4 Biopsy
1.2.5 Other
1.3 麻豆原创 by Application
1.3.1 Global Prostate Cancer Diagnostics Solution 麻豆原创 Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Age Below 55
1.3.3 Age 55-75
1.3.4 Age Above 75
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Prostate Cancer Diagnostics Solution 麻豆原创 Perspective (2020-2031)
2.2 Global Prostate Cancer Diagnostics Solution Growth Trends by Region
2.2.1 Global Prostate Cancer Diagnostics Solution 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2.2 Prostate Cancer Diagnostics Solution Historic 麻豆原创 Size by Region (2020-2025)
2.2.3 Prostate Cancer Diagnostics Solution Forecasted 麻豆原创 Size by Region (2026-2031)
2.3 Prostate Cancer Diagnostics Solution 麻豆原创 Dynamics
2.3.1 Prostate Cancer Diagnostics Solution Industry Trends
2.3.2 Prostate Cancer Diagnostics Solution 麻豆原创 Drivers
2.3.3 Prostate Cancer Diagnostics Solution 麻豆原创 Challenges
2.3.4 Prostate Cancer Diagnostics Solution 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Prostate Cancer Diagnostics Solution Players by Revenue
3.1.1 Global Top Prostate Cancer Diagnostics Solution Players by Revenue (2020-2025)
3.1.2 Global Prostate Cancer Diagnostics Solution Revenue 麻豆原创 Share by Players (2020-2025)
3.2 Global Prostate Cancer Diagnostics Solution 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Prostate Cancer Diagnostics Solution Revenue
3.4 Global Prostate Cancer Diagnostics Solution 麻豆原创 Concentration Ratio
3.4.1 Global Prostate Cancer Diagnostics Solution 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Prostate Cancer Diagnostics Solution Revenue in 2024
3.5 Global Key Players of Prostate Cancer Diagnostics Solution Head office and Area Served
3.6 Global Key Players of Prostate Cancer Diagnostics Solution, Product and Application
3.7 Global Key Players of Prostate Cancer Diagnostics Solution, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Prostate Cancer Diagnostics Solution Breakdown Data by Type
4.1 Global Prostate Cancer Diagnostics Solution Historic 麻豆原创 Size by Type (2020-2025)
4.2 Global Prostate Cancer Diagnostics Solution Forecasted 麻豆原创 Size by Type (2026-2031)
5 Prostate Cancer Diagnostics Solution Breakdown Data by Application
5.1 Global Prostate Cancer Diagnostics Solution Historic 麻豆原创 Size by Application (2020-2025)
5.2 Global Prostate Cancer Diagnostics Solution Forecasted 麻豆原创 Size by Application (2026-2031)
6 North America
6.1 North America Prostate Cancer Diagnostics Solution 麻豆原创 Size (2020-2031)
6.2 North America Prostate Cancer Diagnostics Solution 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Prostate Cancer Diagnostics Solution 麻豆原创 Size by Country (2020-2025)
6.4 North America Prostate Cancer Diagnostics Solution 麻豆原创 Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Prostate Cancer Diagnostics Solution 麻豆原创 Size (2020-2031)
7.2 Europe Prostate Cancer Diagnostics Solution 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Prostate Cancer Diagnostics Solution 麻豆原创 Size by Country (2020-2025)
7.4 Europe Prostate Cancer Diagnostics Solution 麻豆原创 Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Prostate Cancer Diagnostics Solution 麻豆原创 Size (2020-2031)
8.2 Asia-Pacific Prostate Cancer Diagnostics Solution 麻豆原创 Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Prostate Cancer Diagnostics Solution 麻豆原创 Size by Region (2020-2025)
8.4 Asia-Pacific Prostate Cancer Diagnostics Solution 麻豆原创 Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Prostate Cancer Diagnostics Solution 麻豆原创 Size (2020-2031)
9.2 Latin America Prostate Cancer Diagnostics Solution 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Prostate Cancer Diagnostics Solution 麻豆原创 Size by Country (2020-2025)
9.4 Latin America Prostate Cancer Diagnostics Solution 麻豆原创 Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Prostate Cancer Diagnostics Solution 麻豆原创 Size (2020-2031)
10.2 Middle East & Africa Prostate Cancer Diagnostics Solution 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Prostate Cancer Diagnostics Solution 麻豆原创 Size by Country (2020-2025)
10.4 Middle East & Africa Prostate Cancer Diagnostics Solution 麻豆原创 Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 OPKO
11.1.1 OPKO Company Details
11.1.2 OPKO Business Overview
11.1.3 OPKO Prostate Cancer Diagnostics Solution Introduction
11.1.4 OPKO Revenue in Prostate Cancer Diagnostics Solution Business (2020-2025)
11.1.5 OPKO Recent Development
11.2 Genomic Health
11.2.1 Genomic Health Company Details
11.2.2 Genomic Health Business Overview
11.2.3 Genomic Health Prostate Cancer Diagnostics Solution Introduction
11.2.4 Genomic Health Revenue in Prostate Cancer Diagnostics Solution Business (2020-2025)
11.2.5 Genomic Health Recent Development
11.3 Abbott
11.3.1 Abbott Company Details
11.3.2 Abbott Business Overview
11.3.3 Abbott Prostate Cancer Diagnostics Solution Introduction
11.3.4 Abbott Revenue in Prostate Cancer Diagnostics Solution Business (2020-2025)
11.3.5 Abbott Recent Development
11.4 Beckman Coulter
11.4.1 Beckman Coulter Company Details
11.4.2 Beckman Coulter Business Overview
11.4.3 Beckman Coulter Prostate Cancer Diagnostics Solution Introduction
11.4.4 Beckman Coulter Revenue in Prostate Cancer Diagnostics Solution Business (2020-2025)
11.4.5 Beckman Coulter Recent Development
11.5 Siemens Healthcare
11.5.1 Siemens Healthcare Company Details
11.5.2 Siemens Healthcare Business Overview
11.5.3 Siemens Healthcare Prostate Cancer Diagnostics Solution Introduction
11.5.4 Siemens Healthcare Revenue in Prostate Cancer Diagnostics Solution Business (2020-2025)
11.5.5 Siemens Healthcare Recent Development
11.6 bioMeriux
11.6.1 bioMeriux Company Details
11.6.2 bioMeriux Business Overview
11.6.3 bioMeriux Prostate Cancer Diagnostics Solution Introduction
11.6.4 bioMeriux Revenue in Prostate Cancer Diagnostics Solution Business (2020-2025)
11.6.5 bioMeriux Recent Development
11.7 Roche
11.7.1 Roche Company Details
11.7.2 Roche Business Overview
11.7.3 Roche Prostate Cancer Diagnostics Solution Introduction
11.7.4 Roche Revenue in Prostate Cancer Diagnostics Solution Business (2020-2025)
11.7.5 Roche Recent Development
11.8 MDx Health
11.8.1 MDx Health Company Details
11.8.2 MDx Health Business Overview
11.8.3 MDx Health Prostate Cancer Diagnostics Solution Introduction
11.8.4 MDx Health Revenue in Prostate Cancer Diagnostics Solution Business (2020-2025)
11.8.5 MDx Health Recent Development
11.9 DiaSorin
11.9.1 DiaSorin Company Details
11.9.2 DiaSorin Business Overview
11.9.3 DiaSorin Prostate Cancer Diagnostics Solution Introduction
11.9.4 DiaSorin Revenue in Prostate Cancer Diagnostics Solution Business (2020-2025)
11.9.5 DiaSorin Recent Development
11.10 Myriad Genetics
11.10.1 Myriad Genetics Company Details
11.10.2 Myriad Genetics Business Overview
11.10.3 Myriad Genetics Prostate Cancer Diagnostics Solution Introduction
11.10.4 Myriad Genetics Revenue in Prostate Cancer Diagnostics Solution Business (2020-2025)
11.10.5 Myriad Genetics Recent Development
11.11 Ambry Genetics
11.11.1 Ambry Genetics Company Details
11.11.2 Ambry Genetics Business Overview
11.11.3 Ambry Genetics Prostate Cancer Diagnostics Solution Introduction
11.11.4 Ambry Genetics Revenue in Prostate Cancer Diagnostics Solution Business (2020-2025)
11.11.5 Ambry Genetics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

OPKO
Genomic Health
Abbott
Beckman Coulter
Siemens Healthcare
bioMeriux
Roche
MDx Health
DiaSorin
Myriad Genetics
Ambry Genetics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.